154 related articles for article (PubMed ID: 35022817)
1. Phase I study of pegylated liposomal doxorubicin and cisplatin in patients with advanced osteosarcoma.
Wen XZ; Pan QZ; Xu BS; Xiao W; Weng DS; Zhao JJ; Xu HR; Huang Z; Niu XH; Zhang X
Cancer Chemother Pharmacol; 2022 Feb; 89(2):209-215. PubMed ID: 35022817
[TBL] [Abstract][Full Text] [Related]
2. A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
Cheng M; Song Z; Qi Y; Wang X; Zhang L; Shi J; Wang M
Oncol Res Treat; 2019; 42(5):269-274. PubMed ID: 30943501
[TBL] [Abstract][Full Text] [Related]
3. Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies.
Fracasso PM; Rodriguez LC; Herzog TJ; Fears CL; Goodner SA; Govindan R; Picus J; Rader JS; Tan BR; Arquette MA
Cancer; 2003 Aug; 98(3):610-7. PubMed ID: 12879480
[TBL] [Abstract][Full Text] [Related]
4. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup.
Lewis IJ; Nooij MA; Whelan J; Sydes MR; Grimer R; Hogendoorn PC; Memon MA; Weeden S; Uscinska BM; van Glabbeke M; Kirkpatrick A; Hauben EI; Craft AW; Taminiau AH; ;
J Natl Cancer Inst; 2007 Jan; 99(2):112-28. PubMed ID: 17227995
[TBL] [Abstract][Full Text] [Related]
5. Phase I study on pegylated liposomal doxorubicin in combination with docetaxel for patients with platinum-resistant or partially platinum-sensitive epithelial ovarian cancer: The Kansai Clinical Oncology Group study.
Hori K; Ito K; Kuritani K; Kuji S; Furukawa N; Tsubamoto H; Arakawa A
J Cancer Res Ther; 2019; 15(6):1201-1206. PubMed ID: 31898647
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
Eng C; Mauer AM; Fleming GF; Bertucci D; Rotmensch J; Jacobs RH; Ratain MJ
Ann Oncol; 2001 Dec; 12(12):1743-7. PubMed ID: 11843253
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of pegylated liposomal doxorubicin and gemcitabine in patients with advanced malignancies.
Fracasso PM; Blum KA; Tan BR; Fears CL; Bartlett NL; Arquette MA; Clark RS
Cancer; 2002 Nov; 95(10):2223-9. PubMed ID: 12412177
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Kouroussis Ch; Androulakis N; Vamvakas L; Kalykaki A; Spiridonakou S; Kentepozidis N; Saridaki Z; Xiropoulou E; Georgoulias V
Oncology; 2005; 69(3):202-7. PubMed ID: 16127289
[TBL] [Abstract][Full Text] [Related]
9. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
[TBL] [Abstract][Full Text] [Related]
10. A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours.
Bozionelou V; Vamvakas L; Pappas P; Agelaki S; Androulakis N; Kalykaki A; Nikolaidou M; Kentepozidis N; Giassas S; Marselos M; Georgoulias V; Mavroudis D
Br J Cancer; 2007 Jul; 97(1):43-9. PubMed ID: 17551496
[TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
12. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
13. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors.
Dees EC; O'Neil BH; Lindley CM; Collichio F; Carey LA; Collins J; Riordan WJ; Ivanova A; Esseltine D; Orlowski RZ
Cancer Chemother Pharmacol; 2008 Dec; 63(1):99-107. PubMed ID: 18327587
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
17. An escalating dose finding study of liposomal doxorubicin and vinorelbine for the treatment of refractory or resistant epithelial ovarian cancer.
Tambaro R; Greggi S; Iaffaioli RV; Rossi A; Pisano C; Manzione L; Ferrari E; Di Maio M; Iodice F; Casella G; Laurelli G; Pignata S
Ann Oncol; 2003 Sep; 14(9):1406-11. PubMed ID: 12954580
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of oral topotecan and pegylated liposomal doxorubicin (doxil) in platinum-resistant ovarian and peritoneal cancer.
Rose PG; Smrekar M; Haba P; Fusco N; Rodriguez M
Am J Clin Oncol; 2008 Oct; 31(5):476-80. PubMed ID: 18838885
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, paclitaxel and escalating doses of doxorubicin (TAP) in advanced ovarian cancer: a phase I trial.
Onda T; Katsumata N; Tsunematsu R; Yasugi T; Mushika M; Yamamoto K; Fujii T; Hirakawa T; Kamura T; Saito T; Yoshikawa H
Jpn J Clin Oncol; 2004 Sep; 34(9):540-6. PubMed ID: 15466828
[TBL] [Abstract][Full Text] [Related]
20. Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
Ricevuto E; Cocciolone V; Mancini M; Cannita K; Romano S; Bruera G; Pelliccione M; Adinolfi MI; Ciccozzi A; Bafile A; Penco M; Ficorella C
Oncologist; 2015 Feb; 20(2):109-10. PubMed ID: 25601964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
